The mind-bending new rules for doing business in China
Xi Jinping is sending mixed messages to Western bosses and investors
FOR YEARS foreign companies were desperate to get into China, and faced formidable bureaucratic obstacles in their way. Now many are getting out. Over the past 12 months several foreign law firms have closed some or all of their Chinese offices. Orrick, Herrington & Sutcliffe, an American one, said on March 22nd it would shut the Shanghai office it opened 20 years ago. Another, Akin Gump Strauss Hauer & Feld, plans to exit China altogether this year. Some global investment banks are pruning their Chinese staff. So are a few large accountancies and due-diligence groups. In 2023 foreign direct investment in China fell to its lowest level in 30 years.
One reason for foreigners’ change of heart is the sorry state of the Chinese economy. Of the 18 largest multinational companies that report their earnings from China, 13 saw annual revenues there fall in 2023. Qualcomm and Samsung, two technology giants, recorded sales drops of more than 20%. Apple sold nearly a quarter fewer iPhones in the first six weeks of 2024 than it did in the same period the year before. In February Tesla shifted 19% fewer electric cars. Weak Chinese sales are the main reason why Kering, the French owner of Gucci, expected to flog a fifth less of its bling in Asia in the first quarter.
Explore more
This article appeared in the Business section of the print edition under the headline "A new opening?"
Business April 6th 2024
- The mind-bending new rules for doing business in China
- Bob Iger has defeated Nelson Peltz at Disney. Now what?
- India’s biggest conglomerate takes on chipmaking
- Will GE do better as three companies than as one?
- Meet the French oil major that balances growth and greenery
- The six rules of fire drills
- Why Japan Inc is no longer in thrall to America
More from Business
Chinese EV-makers are leaving Western rivals in the dust
They have shone at Beijing’s car jamboree
Can biotech startups upstage Eli Lilly and Novo Nordisk?
Smaller drugmakers are enjoying a revival
How to handle populists: a CEO’s survival guide
Western businesses are learning to live with volatile electoral politics around the world